Aiming at solving the existing issues in purity identification of Cucurbita moschata hybrids by SSR, such as complex operation and difficult application in production practice, in this study, a simple SSR-based method...Aiming at solving the existing issues in purity identification of Cucurbita moschata hybrids by SSR, such as complex operation and difficult application in production practice, in this study, a simple SSR-based method was established for purity identification of Cucurbita moschata hybrids. By using the established simple method, without grinding, freezing, centrifugation and drying, the genomic DNA extraction process is shorter than 3 min. Compared with the conventional method, PCR detection system and silver staining in polyacrylamide gel electrophoresis of the established method are more time-saving and cost-saving. The whole detection process is shorter than 4 h, and 480 samples can be detected with this method by one person in one day. In addition, the detection result exhibits a coincidence rate of 99% with field identification. The simple SSR-based method established in this study can provide basis for large-scale rapid purity identification of Cucurbita moschata hybrids.展开更多
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave.However, the efficacy and safety of azvudine versus Paxlovid are poorly established. Thi...Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave.However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalizedpatients with COVID-19 from eleven hospitals in Henan and Xinjiang Provinces, China. Clinical outcomes were compared betweenthe two drugs via Kaplan–Meier analysis and Cox regression models. Additionally, in vitro and in vivo experiments were used toevaluate the antitumor effects and safety of both drugs. Single-cell RNA sequencing was performed to elucidate the tumor immunelandscape after azvudine treatment. After propensity score matching, 2404 azvudine and 1202 Paxlovid recipients from HenanProvince were included. Cox regression revealed that azvudine was related to an 18% lower risk of all-cause death than Paxlovid(95% CI: 0.676–0.987), was not obviously different in composite disease progression. The robustness of the findings was verified bythe Xinjiang cohort and three sensitivity analyses. Fewer adverse events were observed in the azvudine group. Subgroup analysisrevealed that azvudine provided greater benefits for patients with malignant tumors, significantly reducing both all-cause death(hazard ratio [HR]: 0.33, 95% CI: 0.20−0.54) and composite disease progression (HR: 0.54, 95% CI: 0.33−0.88). Furthermore, azvudinecan suppress the growth of hepatocellular carcinoma (HCC) by regulating CD4+ T and CD8+ T cells in vivo. These findings suggestthat azvudine therapy is not inferior to Paxlovid in hospitalized COVID-19 patients and has fewer adverse effects. Notably, azvudinemay offer greater clinical benefit for patients with HCC.展开更多
基金Supported by Special Fund for Agro-scientific Research in the Public Interest"Technology Research and Demonstration of Pumpkin Industry"(201303112)"Twelfth Five-Year"National Science and Technology Programin Rural Areas"Heterosis Utilization and New Variety Breeding of Pumpkin"(2012BAD02B03-17)
文摘Aiming at solving the existing issues in purity identification of Cucurbita moschata hybrids by SSR, such as complex operation and difficult application in production practice, in this study, a simple SSR-based method was established for purity identification of Cucurbita moschata hybrids. By using the established simple method, without grinding, freezing, centrifugation and drying, the genomic DNA extraction process is shorter than 3 min. Compared with the conventional method, PCR detection system and silver staining in polyacrylamide gel electrophoresis of the established method are more time-saving and cost-saving. The whole detection process is shorter than 4 h, and 480 samples can be detected with this method by one person in one day. In addition, the detection result exhibits a coincidence rate of 99% with field identification. The simple SSR-based method established in this study can provide basis for large-scale rapid purity identification of Cucurbita moschata hybrids.
基金The funding sources of this study are as follows:the National Key Research and Development Program of China(2022YFC2303100 and 2023YFC3043514)the Major Science and Technology Projects in Henan Province(221100310300)+2 种基金Henan Province Epidemic Prevention and Control Emergency Scientific Research Project(221111311600)Henan Province“Three 100”Plan Clinical Medicine Scientist Training Special Project to Z.R.,Key Research and Development projects in Henan Province to Z.R.,Young,and Middle-aged Academic Leaders of Henan Provincial Health Commission(HNSWJW-2022013)the Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University(QNCXTD2023002 and ZYCXTD2023002).
文摘Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave.However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalizedpatients with COVID-19 from eleven hospitals in Henan and Xinjiang Provinces, China. Clinical outcomes were compared betweenthe two drugs via Kaplan–Meier analysis and Cox regression models. Additionally, in vitro and in vivo experiments were used toevaluate the antitumor effects and safety of both drugs. Single-cell RNA sequencing was performed to elucidate the tumor immunelandscape after azvudine treatment. After propensity score matching, 2404 azvudine and 1202 Paxlovid recipients from HenanProvince were included. Cox regression revealed that azvudine was related to an 18% lower risk of all-cause death than Paxlovid(95% CI: 0.676–0.987), was not obviously different in composite disease progression. The robustness of the findings was verified bythe Xinjiang cohort and three sensitivity analyses. Fewer adverse events were observed in the azvudine group. Subgroup analysisrevealed that azvudine provided greater benefits for patients with malignant tumors, significantly reducing both all-cause death(hazard ratio [HR]: 0.33, 95% CI: 0.20−0.54) and composite disease progression (HR: 0.54, 95% CI: 0.33−0.88). Furthermore, azvudinecan suppress the growth of hepatocellular carcinoma (HCC) by regulating CD4+ T and CD8+ T cells in vivo. These findings suggestthat azvudine therapy is not inferior to Paxlovid in hospitalized COVID-19 patients and has fewer adverse effects. Notably, azvudinemay offer greater clinical benefit for patients with HCC.
